Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Novel Antisense Anti-MDM2 Mixed-Backbone Oligonucleotides: Proof of Principle, In Vitro and In Vivo Activities, and Mechanisms

1 Feb 2005

Abstract excerpt

The MDM2 oncogene has been suggested as a novel target for cancer therapy, based on the following observations: 1) MDM2 is overexpressed in many human cancers, including breast, colon, and prostate cancer; 2) high MDM2 levels are associated with poor prognosis in patients with cancer; 3) MDM2 overexpression is associated with advanced cancer phenotypes such as metastatic tumors and hormone-independent tumors; 4)...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer-related Molecular Pathways

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 15720188
DOI: 10.2174/1568009053332663

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Novel Antisense Anti-MDM2 Mixed-Backbone Oligonucleotides: Proof of Principle, In Vitro and In Vivo Activities, and MechanismsPMID 15720188Read ↗

Antisense anti-MDM2 oligonucleotides as a novel therapeutic approach to human breast cancer: in vitro and in vivo activities and mechanisms.Semantic proximity Read ↗

Radiosensitization by antisense anti-MDM2 mixed-backbone oligonucleotide in in vitro and in vivo human cancer models.Semantic proximity Read ↗

Anti-Tumor Efficacy of a Novel Antisense Anti-MDM2 Mixed-Backbone Oligonucleotide in Human Colon Cancer Models: p53-Dependent and p53-Independent MechanismsSemantic proximity Read ↗

Ubiquitous induction of p53 in tumor cells by antisense inhibition of MDM2 expression.Semantic proximity Read ↗

MDM2 oncogene as a target for cancer therapy: An antisense approach.Semantic proximity Read ↗

Antisense therapy targeting MDM2 oncogene in prostate cancer: Effects on proliferation, apoptosis, multiple gene expression, and chemotherapySemantic proximity Read ↗

MDM2 in Tumor Biology and Cancer Therapy: A Review of Current Clinical TrialsSemantic proximity Read ↗

Natural Product MDM2 Inhibitors: Anticancer Activity and Mechanisms of ActionSemantic proximity Read ↗

MDM2 inhibitors in sarcomas: results and next stepsSemantic proximity Read ↗

Targeting Mouse Double Minute 2: Current Concepts in DNA Damage Repair and Therapeutic Approaches in CancerSemantic proximity Read ↗

Clinical Overview of MDM2/X-Targeted TherapiesSemantic proximity Read ↗

Antisense anti-MDM2 mixed-backbone oligonucleotides enhance therapeutic efficacy of topoisomerase I inhibitor irinotecan in nude mice bearing human cancer xenografts: In vivo activity and mechanisms.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.